Sign inJoin waitlistJoin the waitlist

Tobias Walbert

, Program Director · Henry Ford Health

Credentials: · · · · · ·

History

Henry Ford Health
Present
Henry Ford Health
Present
Wayne State University School of Medicine
Present

Henry Ford Hospital
2010–2011
Hospice and Palliative Medicine
2010–2011
Neurology
Case Western Reserve University/University Hospitals Cleveland Medical Center
2005–2009
Internal Medicine
Case Western Reserve University/University Hospitals Cleveland Medical Center
2000–2003
Harvard School of Public Health, MA, 2002
Friedrich Schiller Universitaet
1996–2000
Harvard University

Research

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Journal of Translational Medicine · 2018 · 425 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3…
JAMA Oncology · 2023 · 399 citations
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma
Science Translational Medicine · 2016 · 152 citations

Tom Mikkelsen
17 papers
James Snyder
16 papers
Ian Lee
15 papers
PW
Patrick Wen
15 papers
Louis Nabors
14 papers
Steven Kalkanis
11 papers
SG
Stuart Grossman
11 papers
Howard Colman
8 papers · 7 as a resident
Adam Robin
7 papers
Arati Desai
7 papers
FL
Frank Lieberman
7 papers
Karam Asmaro
7 papers · 7 as a resident

Clinical trials

Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
Principal investigator · Recruiting · Phase 1
Henry Ford Health System
2022–2027
Quality of Life and Patient Needs in Advanced High Grade Gliomas
Principal investigator · Completed
Henry Ford Health System
2012–2023
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Site PI · Recruiting · Phase 1
Orbus Therapeutics, Inc.
2023–2026
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
Site PI · Recruiting · Phase 3
Nuvation Bio Inc.
2023–2030